Navigation Links
Two Drugs Shown to Prolong Survival in Advanced Melanoma Cases

By Amanda Gardner
HealthDay Reporter

SUNDAY, June 5 (HealthDay News) -- Two new drugs prolong the lives of patients with advanced melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure.

The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration. The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March.

Research on both drugs was presented Sunday at the annual meeting of the American Society of Clinical Oncology in Chicago while also being published simultaneously online in the New England Journal of Medicine.

"This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering Cancer Center in New York City, said in a statement. "This [vemurafenib] is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers."

The second study was also led by doctors from Sloan-Kettering.

"Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."

"The March FDA approval of ipilumumab [Yervoy] was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.

In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.

At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.

Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.

This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said.

"There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It's unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.

Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours.

"The median time to progression with dacarbazine was 1.6 months versus 5.3 months with vemurafenib, which is a huge difference," said Chapman.

In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.

Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.

Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.

By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.

The study was sponsored by Bristol-Myers Squibb, which makes Yervoy.

This is the first study to combine chemotherapy and immunotherapy both safely and effectively; a study to test vemurafenib in combination with Yervoy has already begun.

"Neither one are the real answers, but they are steps forward and that's what we need," said Turnham, who added that he thinks the real answers will come in combination therapies.

"We need to be nimble about combination studies," he said. "In the two years that we've known we need to study vemurafenib and ipilumumab [Yervoy], 18,000 people have died of melanoma in the U.S. We can't afford to wait. We're very excited about the positive news, but we have a long way to go."

More information

The Skin Cancer Foundation has more on melanoma.

SOURCES: Tim Turnham, Ph.D., executive director, Melanoma Research Foundation; Stephen Hodi, M.D., director, Melanoma Center, Dana Farber Cancer Institute, Boston; June 5, 2011, New England Journal of Medicine, online; June 5, 2011, presentations, American Society of Clinical Oncology annual meeting, Chicago; June 5, 2011, news conference with Paul Chapman, M.D., attending physician, melanoma/sarcoma service, Memorial Sloan-Kettering Cancer Center, New York City, and Lynn Schuchter, M.D., division chief of hematology-oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Epilepsy Drugs Risk of Birth Defects May Be Dose-Dependent
2. Widely Used Heart Drugs Linked to Better Breast Cancer Outcomes
3. Illegal Drugs Easy to Buy on the Internet, U.K. Study Finds
4. CT angiography for low-risk heart patients leads to more drugs and tests without benefit
5. Younger Docs More Likely to Prescribe Drugs for Heart Disease: Study
6. Standard Heart Drugs Wont Ease Pulmonary Hypertension
7. Half of prostate cancers could potentially benefit from new type of cancer drugs, U-M study finds
8. Kids Taking ADHD Drugs at Low Risk for Heart Problems: Study
9. Younger doctors prescribe more drugs to reduce heart risk but offer less lifestyle advice
10. Abcc10 may be effective in extending the effectiveness of anticancer drugs
11. Researchers move closer to identifying new class of asthma, COPD drugs
Post Your Comments:
Related Image:
Two Drugs Shown to Prolong Survival  in Advanced Melanoma Cases
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its ... Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding ... Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, we ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions ... initiated cultivation and processing operations at its production facility, and opened its first ... is the manufacturer of a complete system of proactive air and surface purification ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
(Date:6/23/2016)... 23, 2016  MedSource announced today that it ... software solution of choice.  This latest decision demonstrates ... to their clients by offering a state-of-the-art electronic ... establishes nowEDC as the EDC platform of choice ... clients.  "nowEDC has long been a preferred EDC ...
Breaking Medicine Technology: